Brief: Celyad Oncology End-Dec Unaudited Treasury Position Of EUR 30 Mln
10/01/2022 06:13
Jan 10 (Reuters) - Celyad Oncology SA CYAD.BR :
* KEYNOTE-B79 AND IMMUNICY-1 CLINICAL TRIALS EVALUATING
COMPANY'S
ALLOGENEIC CAR T CANDIDATES, CYAD-101 AND CYAD-211 RESPECTIVELY,
EXPECTED TO GENERATE KEY DATA THROUGHOUT 2022
* COMPANY'S PROPRIETARY NON-GENE EDITED SHRNA TECHNOLOGY
CLINICALLY VALIDATED AS A NOVEL PLATFORM FOR DEVELOPMENT OF
NEXT-GENERATION, ALLOGENEIC CAR TS
* PRECLINICAL SHRNA-BASED ALLOGENEIC PIPELINE CONTINUES TO
PROGRESS WITH IL-18-ARMORED CAR T CANDIDATE CYAD-203
* RECENT $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS
INVESTMENT
GROUP AFFILIATE TO FUND FURTHER RESEARCH AND DEVELOPMENT OF
COMPANY'S CURRENT ALLOGENEIC CAR T PIPELINE
* AS OF DECEMBER 31, 2021, COMPANY ENDED YEAR WITH AN
UNAUDITED
TREASURY POSITION OF EUR 30 MILLION ($34 MILLION)
* SHRNA-BASED ALLOGENIC PIPELINE CONTINUES TO PROGRESS WITH
DISCOVERY PROGRAMS FOCUSED ON IN-LICENSED T-CELL ENGAGERS
TARGETING TAG72 AND GPC3
* ENROLLMENT IN COHORTS EVALUATING ENHANCED LYMPHODEPLETION
IS
ONGOING AND ADDITIONAL DATA FROM CYAD-211 IMMUNICY-1 TRIAL ARE
EXPECTED IN MID-2022
* ENROLLMENT CONTINUES IN KEYNOTE-B79 PHASE 1B TRIAL FOR
CYAD-101;
PRELIMINARY DATA FROM TRIAL ARE EXPECTED IN SECOND HALF OF 2022
* INVESTIGATIONAL NEW DRUG (IND)-ENABLING STUDIES CONTINUE
FOR
CYAD-203. SUBMISSION OF IND APPLICATION FOR CYAD-203 IS EXPECTED
IN H2 2022
Source text for Eikon: ID:nBw4wTKKNa
Further company coverage: CYAD.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))